share_log

HC Wainwright & Co. Maintains Buy on CARISMA Therapeutics, Lowers Price Target to $9

HC Wainwright & Co. Maintains Buy on CARISMA Therapeutics, Lowers Price Target to $9

HC Wainwright & Co.維持對CARISMA Therapeutics的買入,將目標股價下調至9美元
Benzinga ·  04/02 08:51

HC Wainwright & Co. analyst Mitchell Kapoor maintains CARISMA Therapeutics (NASDAQ:CARM) with a Buy and lowers the price target from $11 to $9.

HC Wainwright & Co. 分析師米切爾·卡普爾維持CARISMA Therapeutics(納斯達克股票代碼:CARM)的買入並將目標股價從11美元下調至9美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論